Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1995-1-30
|
pubmed:abstractText |
Our aim was to investigate the existence of an association between B cell responsiveness to hepatitis C virus (HCV) core protein and progression of liver disease. In fact, the persistence of HCV infection is permitted by avoidance of viral clearance, despite chronic inflammation in the liver; this process ends with the development of hepatocellular carcinoma in many patients. On the basis of computerized prediction of antigenicity of the genomic sequence of HCV core protein, three 15-mer peptides (named Q15V, R15P, and G15V) were synthesized to be used as antigens in an enzyme immunoassay. Sera from 97 patients (65 males and 32 females) were tested: 43 patients had mild chronic liver disease (steatofibrosis, chronic persistent, or chronic active hepatitis) and 54 had cirrhosis, which was complicated by hepatocellular carcinoma (HCC) in 19. Seventy-six patients were positive to anti-HCV testing by second generation ELISA and 21 were negative. Rates of positivity for synthetic peptides in anti-HCV-positive versus anti-HCV negative patients were as follows: 53 of 76 and 0 of 21 for anti-Q15V; 41 of 76 and 0 of 21 for R15P; and 67 of 76 and 2 of 21 for G15V. Rates of positivity to anti-Q15V and anti-G15V were similar among diagnostic groups (Pearson's chi 2, 1.97, P > 0.10 and 0.45, P > 0.10), whereas anti-R15P antibodies were detected at a significantly lower rate in patients with HCC (2/13) in comparison to mild chronic liver disease (22/35) and cirrhosis (17/28) (Pearson's chi 2, 9.42, P < 0.01). We conclude that anti-R15P antibodies are uncommon in anti-HCV-positive patients with HCC. During the course of chronic HCV infection, anti-R15P testing might help to identify a subgroup at higher risk to develop HCC.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0008-5472
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
55
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
111-4
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:7528637-Adult,
pubmed-meshheading:7528637-Aged,
pubmed-meshheading:7528637-Amino Acid Sequence,
pubmed-meshheading:7528637-B-Lymphocytes,
pubmed-meshheading:7528637-Base Sequence,
pubmed-meshheading:7528637-Carcinoma, Hepatocellular,
pubmed-meshheading:7528637-Disease Progression,
pubmed-meshheading:7528637-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:7528637-Epitopes,
pubmed-meshheading:7528637-Female,
pubmed-meshheading:7528637-Hepatitis Antibodies,
pubmed-meshheading:7528637-Humans,
pubmed-meshheading:7528637-Liver Neoplasms,
pubmed-meshheading:7528637-Male,
pubmed-meshheading:7528637-Middle Aged,
pubmed-meshheading:7528637-Molecular Sequence Data,
pubmed-meshheading:7528637-Viral Core Proteins
|
pubmed:year |
1995
|
pubmed:articleTitle |
Reactivity to B cell epitopes within hepatitis C virus core protein and hepatocellular carcinoma.
|
pubmed:affiliation |
Department of Experimental and Clinical Pathology and Medicine, University of Udine, Italy.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|